SCHEMBL14745449

SCHEMBL14745449

CCc1c(-c2ccc(N3CC=CC3)cc2)[nH]c(=O)c(C(=O)OC)c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
USP2 O75604 1/20 0.38
KCNH2 Q12809 1/20 0.37
DCTPP1 Q9H773 1/20 0.36
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HPGD P15428 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 2/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PADI4 Q9UM07 1/20 0.34
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745803 0.90 DCTPP1 (0.40) GAAMAPTLMNAUSP2KCNH2
SCHEMBL14745632 0.87 KCNH2 (0.38) GAAMAPTKCNH2ALDH1A1POLB
SCHEMBL14744922 0.79 PARP1 (0.38) GAAMAPTLMNAUSP2KDM4E
SCHEMBL16568280 0.78 TLR9 (0.40) GAAMAPTLMNATLR9TLR8
SCHEMBL14745380 0.78 QDPR (0.41) GAAMAPTLMNAUSP2TLR9
SCHEMBL14747044 0.77 KIF11 (0.41) MAPTLMNAKCNH2ALDH1A1HPGD
SCHEMBL14746079 0.77 PDE3B (0.40) GAAMAPTLMNAALDH1A1KDM4E
SCHEMBL14745174 0.77 KCNH2 (0.40) MAPTUSP2KCNH2DCTPP1ALDH1A1
SCHEMBL14745564 0.76 KIF11 (0.42) KCNH2ALDH1A1MEN1KMT2APOLB
SCHEMBL14745189 0.76 KCNH2 (0.41) MAPTUSP2KCNH2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9650395-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2017-05-16 US disclosed
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-03-19 US disclosed
EP-2750505-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033240-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080362-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP GAA 91/4885MAPT 4110/4885LMNA 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.